



Customer Update

Dortmund and Martinsried/Munich, May 3, 2007

MorphoSys' AbD Serotec and Chimera Biotec Extend Cooperation and Co-Marketing Agreement

AbD Serotec, a Division of MorphoSys AG, Munich, and Chimera Biotec GmbH today announced the extension of a co-marketing agreement between the two companies. Within the scope of the agreement the parties agreed to co-market the rapid generation of monoclonal antibodies by AbD Serotec and Chimera Biotec's complementary Imperacer™ assay technology for ultra-sensitive antigen detection. Each partner will offer the services of the other to its customers throughout the world-wide market.

The Imperacer™ technology combines the advantages of flexible and robust protein detection through ELISA with the exponential signal amplification typical for PCR. Imperacer™ uses antibody-DNA conjugates as a substitute for the antibody-enzyme conjugate used in ELISA. Amplifying the conjugated marker-DNA typically results in a 100 – 10,000-fold increase in sensitivity over enzyme-linked assays. Imperacer™ is currently used in human and veterinary diagnostics, bio-pharmaceutical research, biological defense, and in the food, beverage, and cosmetics industries. It is used for a wide variety of highly sensitive analytic applications such as pharmaceutical R&D, first-in human studies, virus detection, prion analysis, pharmacokinetic studies, detection of toxins in food and beverages, and quality assurance for cosmetics.

AbD Serotec uses HuCAL GOLD®, a proprietary recombinant antibody library technology to select antibodies against any given antigen in record time. The process is performed entirely in vitro, and no laboratory animals are involved. Pre-adsorption and intelligent counter-screening during the antibody generation process is used to drive the selection towards the unique epitopes on the antigen. This allows the selection and purification of highly specific antibodies in just 8 weeks. Rapid monoclonal antibody generation service using HuCAL GOLD® is offered worldwide to researchers both from academia and industry.

“The high sensitivity of the Imperacer™ system demands highly specific antibodies to be effective, and many of our customers are seeking such antibodies for these assays,” commented Jan Detmers, Business Development Manager of Chimera Biotec. “We believe that the AbD Serotec process is ideal for rapidly generating antibodies with the specificity our customers need in order for us to be able to develop the best assay.”

About Chimera Biotec GmbH:

Chimera Biotec GmbH develops and markets ultra sensitive immunoassays based on the company's proprietary Imperacer™ technology. Founded in 2000 Chimera Biotec supplies ultra sensitive assays to more than 10 biopharmaceutical companies in Europe and the U.S. Additionally, Chimera Biotec customizes assays for a variety of applications like veterinarian diagnostics, biomarker analytics and for the food, beverage, and cosmetics industries. Being the only commercial provider of immuno-PCR assays, which are 100-10,000 fold more sensitive than conventional ELISAs, Chimera Biotec focuses on ambitious fields like ultra sensitive detection of CNS markers in neurodegenerative diseases, pharmacokinetics, detection of toxins in food and beverage, biomarker analytics, quality assurance in cosmetics, anti doping testing, and many more. In addition to its services Chimera Biotec offers standard detection reagents and secondary assays being compatible to commercially available ELISA kits. For further information, please visit the corporate website at: <http://www.chimera-biotec.com>.

About MorphoSys' AbD Serotec :

MorphoSys develops and applies innovative technologies for the production of synthetic antibodies which accelerate drug discovery and target characterization. Founded in 1992, the Company's proprietary Human Combinatorial Antibody Library (HuCAL®) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing and research collaborations with Bayer (Berkeley, California/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb (New Jersey/USA), Centocor Inc. (Malvern, Pennsylvania/USA), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Merck & Co., Inc. (New Jersey/USA), Novartis AG (Basel, Switzerland), Novoplant GmbH (Gatersleben, Germany), Pfizer Inc. (Delaware/USA), ProChon Biotech Ltd. (Rehovot/Israel), Schering AG (Berlin/Germany), Shionogi & Co., Ltd. (Japan), Xoma Ltd. (Berkeley, California/USA) and others. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. AbD Serotec was founded in 2003 for the purpose of exploiting the MorphoSys non-therapeutic antibody markets. MorphoSys' activities in the research antibody segment were significantly strengthened through the acquisition of the U.K. and U.S.-based Biogenesis Group in January 2005 and the Serotec Group in 2006. For further information, please visit the corporate website at: <http://www.morphosys.com/>; information on the AbD Serotec Division of MorphoSys is available at www.A-by-D.com.

Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the prospectus relating to the company's recent public offering.

For further information please contact:

Chimera Biotec GmbH

Jan Detmers
CEO / Geschäftsführer
Chimera Biotec GmbH
Emil-Figge-Str. 76A
44227 Dortmund
Germany
Phone: +49 (0)231 - 9742 840
Fax: +49 (0)231 - 9742 844
E-mail: info@chimera-biotec.com
Web: www.chimera-biotec.com

AbD Serotec

Business Development queries:

Dieter Lingelbach
Senior Vice President
AbD Serotec / MorphoSys
Lena-Christ-Str. 48
82152 Martinsried / Planegg
Germany
Tel: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: Antibodies@A-by-D.com
Web: www.a-by-d.com

Press and Investor queries:

Dave Lemus
MorphoSys AG
Chief Financial Officer
Tel: +49 (0)89 899 27-439
Fax: +49 (0)89 899 27-5439
E-mail: investors@morphosys.com
Web: www.morphosys.com